Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
1.450
-0.040 (-2.68%)
At close: Aug 1, 2025, 4:00 PM
1.440
-0.010 (-0.69%)
After-hours: Aug 1, 2025, 5:42 PM EDT
R1 RCM Revenue
Alector had revenue of $3.67M in the quarter ending March 31, 2025, a decrease of -76.88%. This brings the company's revenue in the last twelve months to $88.34M, down -8.37% year-over-year. In the year 2024, Alector had annual revenue of $100.56M with 3.60% growth.
Revenue (ttm)
$88.34M
Revenue Growth
-8.37%
P/S Ratio
1.61
Revenue / Employee
$371,172
Employees
238
Market Cap
144.99M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 100.56M | 3.50M | 3.60% |
Dec 31, 2023 | 97.06M | -36.56M | -27.36% |
Dec 31, 2022 | 133.62M | -73.47M | -35.48% |
Dec 31, 2021 | 207.09M | 185.99M | 881.54% |
Dec 31, 2020 | 21.10M | -121.00K | -0.57% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 57.37B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ALEC News
- 1 day ago - Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call - GlobeNewsWire
- 7 weeks ago - Alector Provides Executive Leadership Update - GlobeNewsWire
- 2 months ago - Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Alector Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Alector to Participate in Upcoming Healthcare Conferences - GlobeNewsWire
- 3 months ago - Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease - GlobeNewsWire
- 5 months ago - Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire